Brain, Vol. 126, No. 5, 1127-1135,
May 2003
© 2003 Guarantors of Brain
doi: 10.1093/brain/awg119
Progressive striatal and cortical dopamine receptor dysfunction in Huntington’s disease: a PET study
1 MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, 2 Centre for Brain Repair, University of Cambridge, 3 School of Biosciences, University of Cardiff, UK
Correspondence to: Dr Paola Piccini, MRC Cyclotron Building, Faculty of Medicine, Imperial College School of Medicine, Hammersmith Campus, Du Cane Road, London W12 0NN, UK E-mail: paola.piccini{at}csc.mrc.ac.uk
We have studied the progression of striatal and extrastriatal post-synaptic dopaminergic changes in a group of 12 patients with Huntington’s disease using serial 11C-raclopride PET, a specific marker of D2 dopamine receptor binding. All patients had two 11C-raclopride PET scans 29.2 ± 12.8 months apart, and six of them had a third scan 13.2 ± 3.9 months later. We found a mean annual 4.8% loss of striatal 11C-raclopride binding potential (BP) between the first and second scans, and a 5.2% loss between the second and third scans. Statistical Parametric Mapping (SPM) localized significant baseline reductions in 11C-raclopride BP in both striatal and extrastriatal areas, including amygdala, temporal and frontal cortex in Huntington’s disease compared with normal subjects matched for age and sex. When the 11C-raclopride scans performed 29 months after the baseline scans were considered, SPM revealed further significant striatal, frontal and temporal reductions in 11C-raclopride BP in Huntington’s disease. Cross-sectional Unified Huntington’s Disease Rating Scale (UHDRS) scores correlated with 11C-raclopride binding, but there was no correlation between individual changes in UHDRS motor scores and changes in striatal binding. Performance on all neuropsychological measures deteriorated with time but only the accuracy score of the one-touch Tower of London test correlated significantly with striatal and putamen D2 binding. In summary, serial 11C-raclopride PET demonstrates a linear progression of striatal loss of D2 receptors in early clinically affected Huntington’s disease patients over 3 years. SPM also revealed a progressive loss of temporal and frontal D2 binding. Changes over time in clinical scores and in neuropsychological assessments, except for measures of planning, did not correlate with striatal D2 binding. This probably reflects both contributions from other affected brain structures and high variance in these measures.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Politis, N. Pavese, Y. F. Tai, S. J. Tabrizi, R. A. Barker, and P. Piccini Hypothalamic involvement in Huntington's disease: an in vivo PET study Brain, October 1, 2008; (2008) awn244v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Feigin, C. Tang, Y. Ma, P. Mattis, D. Zgaljardic, M. Guttman, J. S. Paulsen, V. Dhawan, and D. Eidelberg Thalamic metabolism and symptom onset in preclinical Huntington's disease Brain, November 1, 2007; 130(11): 2858 - 2867. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Binkofski, K. Reetz, C. Gaser, R. Hilker, J. Hagenah, K. Hedrich, T. van Eimeren, A. Thiel, C. Buchel, P. P. Pramstaller, et al. Morphometric fingerprint of asymptomatic Parkin and PINK1 mutation carriers in the basal ganglia Neurology, August 28, 2007; 69(9): 842 - 850. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. F. Tai, N. Pavese, A. Gerhard, S. J. Tabrizi, R. A. Barker, D. J. Brooks, and P. Piccini Microglial activation in presymptomatic Huntington's disease gene carriers Brain, July 1, 2007; 130(7): 1759 - 1766. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Gantois, K. Fang, L. Jiang, D. Babovic, A. J. Lawrence, V. Ferreri, Y. Teper, B. Jupp, J. Ziebell, C. M. Morganti-Kossmann, et al. Ablation of D1 dopamine receptor-expressing cells generates mice with seizures, dystonia, hyperactivity, and impaired oral behavior PNAS, March 6, 2007; 104(10): 4182 - 4187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Pavese, A. Gerhard, Y. F. Tai, A. K. Ho, F. Turkheimer, R. A. Barker, D. J. Brooks, and P. Piccini Microglial activation correlates with severity in Huntington disease: A clinical and PET study Neurology, June 13, 2006; 66(11): 1638 - 1643. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.C.H. van Oostrom, R. P. Maguire, C. C. Verschuuren-Bemelmans, L. Veenma-van der Duin, J. Pruim, R. A.C. Roos, and K. L. Leenders Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease Neurology, September 27, 2005; 65(6): 941 - 943. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Scherfler, N. L. Khan, N. Pavese, L. Eunson, E. Graham, A. J. Lees, N. P. Quinn, N. W. Wood, D. J. Brooks, and P. P. Piccini Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism Brain, June 1, 2004; 127(6): 1332 - 1342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y F Tai and P Piccini Applications of positron emission tomography (PET) in neurology J. Neurol. Neurosurg. Psychiatry, May 1, 2004; 75(5): 669 - 676. [Abstract] [Full Text] [PDF]
|
|